Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Room 3250 - East Wing - Health Sciences Boulevard, 104 Clinic Place, Saskatoon, Saskatchewan S7N 2Z4, Canada.
Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, 1600 7th Avenue South, CPPN G10, Birmingham, AL 35233, USA.
Rheum Dis Clin North Am. 2021 Nov;47(4):643-653. doi: 10.1016/j.rdc.2021.07.012. Epub 2021 Sep 2.
The advent of biologic disease-modifying antirheumatic drugs targeting specific cytokines or cell-cell interactions has dramatically changed the outlook of patients with juvenile idiopathic arthritis. However, safety concerns remain around the use of therapeutic agents for children with juvenile idiopathic arthritis. Foremost among these are the risks of serious infections and malignancy. This article provides an overview of methodologies for pharmacosurveillance in juvenile idiopathic arthritis, including spontaneous reporting systems and the use of diverse data sources, such as electronic health records, administrative claims, and clinical registries. The risks of infections and malignancies are then briefly reviewed.
生物靶向特定细胞因子或细胞间相互作用的疾病修饰抗风湿药物的出现，极大地改变了幼年特发性关节炎患者的预后。然而，儿童使用治疗药物的安全性仍令人担忧，其中最主要的是严重感染和恶性肿瘤的风险。本文概述了幼年特发性关节炎药物监测的方法学，包括自发报告系统和使用多种数据源，如电子健康记录、行政索赔和临床登记。随后简要回顾了感染和恶性肿瘤的风险。
